01 Jul 2024 - 29 Jul 2024


CS-IRG New Investigator Grant (CS-IRG-NIG) is a sub category of the CS-IRG to cater for new clinical investigators. The CS-IRG-NIG is a step for the new investigator towards winning a first independent national level grant. Applicants with substantial research experience will not be accepted under this category.

Research Themes:

The CS-IRG-NIG is open to application on all research themes. Applications are assessed based on scientific merit and relevance to Singapore, but should prioritisation be required between meritorious applications, the following seven disease areas have been identified as national priorities for research:

  • Cancers and neoplasms
  • Cardiovascular
  • Eye
  • Infection
  • Mental health
  • Metabolic and endocrine
  • Neurological

Evaluation Criteria:

Selection of successful proposals would be based on the following evaluation criteria:

  • Scientific excellence
  • Feasibility of study in local context
  • Productivity
  • Overall impact in local context
  • Suitability of applicant to be an independent investigator and to assume the role of a PI

To be eligible for the CS-IRG-NIG, the following requirements apply:

(i) Awardees of the following grants as PI/Co-PI* at the point of application will not be eligible for the NIG: A*STAR Investigatorship, NRF Fellowship, NMRC CSA and STaR, MOE Tier 2 and 3 grants, MOH/NMRC IRG-equivalent grants^.

*Co-PIs refer to PIs whose projects are jointly led by other PIs (e.g. projects under NMRC’s Bedside & Bench grant). They are not the same as, and should not be confused with Co-Investigators (Co-Is).
^NIC Ageing Grants (with the exception of Health and Longevity Catalyst Awards) are considered IRG-equivalent grants.

(ii) Applicants must not have received external competitive funding exceeding $500,000 (direct costs only), to conduct their own research project as the PI. 

Applicants who are applying under the new investigator category (CS-IRG-NIG) have to work with a mentor for guidance in their research. This mentoring will provide support for a period of supervised research leading eventually to the clinical investigators conducting larger scale research projects independently. Please note that the NIG is intended to fund a new investigator’s independent project, and not to provide additional funding for the mentor's project (or clinical trial). 


Each CS-IRG-NIG application must be led by a Clinical Principal Investigator (PI) who has to fulfill the eligibility criteria listed below:

  1. PI must be clinically qualified (i.e. with MD/MBBS/BDS) and preferably with post-graduate clinical training and experience.
  2. Allied Health Professionals who meet the following conditions may apply:
    1. Non-medically trained PIs who are nurses, pharmacists or other allied health professions listed on the MOH’s website in clinical practice, doing research in clinical settings or doing research with clinical and healthcare applications/relevance, are eligible to apply.
    2. Applicants who are working in human clinical research, including epidemiologists, biostatisticians, and whose research is clinically relevant and has potential health impact, will be considered as exceptions on a case-by-case basis.
    3. Non-medically trained applicants conducting wet laboratory based research are not eligible.
    4. Applicants must possess a minimum academic qualification of a PhD or the equivalent training.
    5. Recipients of NMRC Human Capital Awards, Transition Award and NMRC Research Training Fellowship are eligible to apply.
  3. A*STAR CS scholar from the National Science Scholarship (NSS) (MBBS-PhD) or NSS (MD-PhD) schemes and who fulfil the following may apply:
    1. hold primary appointments in Academic Medical Centres (AMCs), public health institutions (PHIs) or medical schools; or
    2. hold primary appointments in A*STAR but (with mutual agreement of A*STAR and the AMC/PHI/medical school) also hold a joint appointment in the AMC/PHI/medical school, provided that any such grant application is supported by the AMC/PHI/medical school.The institution/school should also consider if these A*STAR CS scholars are able to demonstrate that they can act as a bridge between A*STAR and the healthcare system.
    3. submit the grant application through AMCs/PHIs/medical schools as host institutions.
  4. For proposals involving patients, the clinical PI or co-I should be SMC registered; or should be able to demonstrate ability to access patients through SMC registered collaborators. For some CS-IRG-NIG proposals it is recognized that some studies may be pre-clinical and not require the PI to be SMC registered.
  5. Only one PI is allowed per application. The number of applications by an individual (as PI) is capped at 1 grant application per grant type in a grant call.

Additional eligibility criteria include:

(a)  Hold a primary appointment in a local public hospital/public health institutions/national specialty centre/public universities/Academic Medical Centres and salaried by the institution.

(b) Demonstrate relevant interest in research as evidenced by recent past work, including but not limited to clinical work, publications, participation in research studies etc.

(c) Have access to a laboratory or clinical research program that carries out research in Singapore.

(d)  Hold a minimum of 9 months employment with a local public institution. Upon award, the PI must agree to fulfill at least 6 months of residency in Singapore for each calendar year over the duration of the grant award. 

(e) No outstanding reports from previous BMRC, NMRC grants and other national grants.

Funding Quantum:

The CS-IRG-NIG will provide a funding quantum of up to S$260,000  (inclusive of up to 30% indirect costs^) for up to 2 years.  Projects involving prospective patient/subject recruitment may apply for a funding duration of up to 3 years, subject to the same funding quantum.

^Indirect costs is not applicable for research scholarship budget.

Grant Call Frequency:

There will be two grant calls per year (Jan and Jul). 


It is mandatory for all applications to be submitted and endorsed by the Host Institution's Director of Research (DOR) online via IGMS by 29 July 2024, 5pm. We will not entertain any late submissions or submissions from individual applicants without endorsement from the Host Institution.

Please download the CS-IRG-NIG Guide and Application Form for more information. 

Review Panel:

The composition of the CS-IRG/NIG Review Panel 2024-2026 is listed in the table below.

S/N Name Institution
1 Prof Yap Seng CHONG (Co-Chair) Dean, Yong Loo Lin School of Medicine, National University of Singapore
Lien Ying Chow Professor in Medicine, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore
Deputy Chief Executive (Education & Research), National University Health System
Chief Clinical Officer, Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR)

Prof Joseph SUNG

Distinguished University Professor
Dean, Lee Kong Chian School of Medicine
Senior Vice President (Health and Life Sciences)
Nanyang Technological University, Singapore
3 A/Prof Rinkoo DALAN Senior Consultant, Endocrinology, TTSH
Associate Professor, Lee Kong Chian School of Medicine, NTU
4 A/Prof Chester DRUM Associate Professor and Senior Consultant, Dept of Medicine, Yong Loo Lin School of Medicine,
National University of Singapore
5 Prof Derek HAUSENLOY Professor, Duke-NUS Medical School
Senior Consultant Cardiologist and Clinician Scientist, National Heart Centre, Singapore
6 Prof Gopal IYER Head & Senior Consultant, Division of Surgery & Surgical Oncology, National Cancer Centre Singapore
Senior Consultant, SingHealth Duke-NUS Head and Neck Centre
Head & Senior Consultant, Head & Neck Surgery, Singapore General Hospital
7 Prof Ecosse LAMOUREUX  Professor, SingHealth Duke-NUS Ophthalmology & Visual Sciences Academic Clinical Programme
Director of the Population Research and Clinical Epidemiology platform, Singapore Eye Research Institute
8 Prof Soo Chin LEE Head & Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
9 A/Prof Kandiah NAGAENDRAN Associate Professor of Neuroscience, Lee Kong Chian School of Medicine, Nanyang Technological University
Senior Consultant, Department of Neurology, National Neuroscience Institute
Director, Clinical Research, Neuroscience Academic Clinical Programme
10 A/Prof Joanne NGEOW Associate Professor, Genomic Medicine, Lee Kong Chian School of Medicine
Associate Professor, Lee Kong Chian School of Medicine
Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore
11 Prof Ee Chee REN Adjunct Associate Professor
Department of Microbiology & Immunology
Yong Loo Lin School of Medicine, NUS
12 A/Prof Vijay K SHARMA Associate Professor, Yong Loo Lin School of Medicine, National University of Singapore.
Senior Consultant, Division of Neurology, Department of Medicine, National University Hospital
13 Prof Yik Ying TEO Dean, Saw Swee Hock School of Public Health, NUS
Department of Statistics and Applied Probability, Faculty of Science, NUS
14 Prof David VIRSHUP Honorary Joint Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, NUS.
Program Director for Cancer & Stem Cell Biology, Duke-NUS Graduate Medical School
15 A/Prof Sunny Hei WONG Associate Professor of Nutrition, Digestion and Metabolism and Assistant Dean, Academic Medicine, Lee Kong Chian School of Medicine
Associate Professor, Lee Kong Chian School of Medicine
16 A/Prof Barnaby Edward YOUNG
Head, Infectious Disease Research Ward; Senior Consultant
National Centre for Infectious Diseases
17 Prof Ian CAMPBELL Co-Head, Women’s Cancer Program, Peter MacCallum Cancer Centre
Head, Cancer Genetics Laboratory, Sir Peter MacCallum Department of Oncology at the University of Melbourne, Australia
Principal Investigator, Lifepool
18 Prof Bernard CHEUNG Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics
Chief, Division of Clinical Pharmacology & Therapeutics, Department of Medicine, University of Hong Kong, Hong Kong
19 Prof Mark COOPER Head of Department of Diabetes, Central Clinical School, Monash University, Australia
20 Prof Masaru KATOH Doctorate, National Cancer Centre, Tokyo, Japan
21 Prof Thomas KLIMKAIT Project Leader, University of Basel, Switzerland
22 Prof Linda LAM Professor and Chairman, Department of Psychiatry, The Chinese University of Hong Kong (CUHK), Hong Kong
23 Prof Andrew LOTERY Professor of Ophthalmology
University of Southampton, United Kingdom
24 Prof Andreas MOLLER Professor, Department of Otorhinolaryngology, Head and Neck Surgery
The Chinese University of Hong Kong (CUHK), Hong Kong
25 Prof Guang NING Professor
Ruijin Hospital, Shanghai Jiao Tong University of Medicine, China
26 Prof Matthias OCKER Faculty member and adjunct professor of experimental medicine, Charité University Medicine Berlin, Germany
Department of Hematology, Oncology and Cancer Immunology (CCM)
Vice President of Translational Medicine, Anji Pharma
27 Prof Kyong Soo PARK Director, Center for Precision Medicine, Seoul National University, Korea 
28 Prof Takeshi SAKURAI Professor of Department of Drug Discovery Medicine, Medical Innovation Center, Kyoto University Graduate School of Medicine, Japan
29 Prof Mark SCHEMBRI Professor
School of Chemistry and Molecular Biosciences
The University of Queensland, Australia
30 Prof Gerald TANNOCK Emeritus Professor, University of Otago, New Zealand

Applicants are not allowed to approach any of the panel members to discuss or solicit information related to their application review or funding decisions. NMRC may impose a suspension and/or debarment on such applicants.